Citadel Advisors’s scPharmaceuticals SCPH Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-11,900
| Closed | -$67.5K | – | 13913 |
|
|
2025
Q3 | $67.5K | Buy |
+11,900
| New | +$60.9K | ﹤0.01% | 12055 |
|
|
2025
Q2 | – | Sell |
-2,000
| Closed | -$5.26K | – | 14768 |
|
|
2025
Q1 | $5.26K | Sell |
2,000
-18,800
| -90% | -$61.2K | ﹤0.01% | 13829 |
|
|
2024
Q4 | $73.6K | Buy |
20,800
+8,700
| +72% | +$33.3K | ﹤0.01% | 11898 |
|
|
2024
Q3 | $55.2K | Buy |
12,100
+9,500
| +365% | +$46K | ﹤0.01% | 11801 |
|
|
2024
Q2 | $11.3K | Sell |
2,600
-300
| -10% | -$1.32K | ﹤0.01% | 13045 |
|
|
2024
Q1 | $14.6K | Sell |
2,900
-10,000
| -78% | -$56K | ﹤0.01% | 13234 |
|
|
2023
Q4 | $80.9K | Buy |
12,900
+10,000
| +345% | +$57.3K | ﹤0.01% | 11210 |
|
|
2023
Q3 | $20.6K | Sell |
2,900
-21,000
| -88% | -$165K | ﹤0.01% | 12608 |
|
|
2023
Q2 | $244K | Buy |
23,900
+21,100
| +754% | +$220K | ﹤0.01% | 9463 |
|
|
2023
Q1 | $25.4K | Sell |
2,800
-35,600
| -93% | -$261K | ﹤0.01% | 12874 |
|
|
2022
Q4 | $275K | Buy |
38,400
+25,800
| +205% | +$158K | ﹤0.01% | 9504 |
|
|
2022
Q3 | $82K | Buy |
+12,600
| New | +$67.3K | ﹤0.01% | 11261 |
|
Citadel Advisors's SCPH Position: Q4 2025 in Review
Citadel Advisors sold out of scPharmaceuticals (SCPH) in Q4 2025, closing a stake of 157,217 shares — an estimated $891K sold.
Citadel Advisors first reported a position in SCPH in Q2 2018 and held it in 16 quarters. The position peaked at $3.2M in Q2 2024. 0 funds tracked by Wall St. Rank hold SCPH as of Q4 2025.
- Citadel Advisors reported no remaining scPharmaceuticals position as of Q4 2025 after selling out during the quarter.
- Citadel Advisors sold 157,217 scPharmaceuticals shares in Q4 2025, an estimated $891K.
- Citadel Advisors first reported a position in scPharmaceuticals in Q2 2018 and held it in 16 quarters.
- Citadel Advisors's scPharmaceuticals position peaked at $3.2M in Q2 2024.
- 0 funds tracked by Wall St. Rank held scPharmaceuticals as of Q4 2025.
Based on Citadel Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.